Business Context and Reporting Period
Company: Inmune Bio, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: December 19, 2025
Event: Entry into a Material Definitive Agreement (Sales Agreement).
Key Financial Metrics
This filing does not report revenue, profit, cash flow, margins, debt, or liquidity metrics. It discloses the following capital market activity:
- Offering Capacity: Up to $65,000,000 of common stock.
- Commission Rate: 3.0% of aggregate gross proceeds.
- Trading Symbol: INMB (NASDAQ).
Material Changes
On December 19, 2025, the Company entered into a Sales Agreement with A.G.P./Alliance Global Partners ("A.G.P."). Under this agreement:
- The Company may offer and sell shares of common stock through A.G.P. as sales agent in "at the market" offerings.
- The Company is not obligated to sell any shares.
- Sales are subject to the Company's instructions regarding price, time, and size limits.
- The offering is conducted pursuant to an effective shelf registration statement on Form S-3 (File No. 279036).
Guidance, Outlook, and Risks
Management Commentary: The filing states that A.G.P. will use commercially reasonable efforts to sell shares consistent with normal trading practices and applicable laws. The Company has agreed to reimburse A.G.P. for certain specified expenses and provide customary indemnification rights.
Risks and Contingencies: The Company's ability to sell shares is subject to satisfaction of certain conditions, including customary closing conditions. The filing does not provide specific forward-looking financial guidance or operational outlook beyond the terms of the sales agreement.
Investor Verification Checklist
- Verify the current market price of INMB to assess potential dilution impact from the $65,000,000 offering capacity.
- Review the full text of the Sales Agreement (Exhibit 1.1) for specific termination rights and conditions.
- Confirm the Company's current cash position in the most recent 10-Q or 10-K to understand the necessity of this capital raise.
- Monitor future filings for actual sales volumes and proceeds generated under this agreement.